More clinical trials are conducted in multi-countries, such as Asia, Latin America, or Central and Eastern Europe. Even US-based studies recruit the majority of the subjects for clinical studies outside the US. Translation is required at many stages in bringing a drug to market, including regulatory submissions, clinical research, manufacturing, packaging and marketing. Erroneous translation can have exceptionally high indirect costs, leading to the delay of product commercialization, raising the possibility of litigation or rejection by regulators.